-
After Tocilizumab, IL-6 Goes Up. That Is the Drug Working.(Post)
Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b
Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
Mycoplasma in Cell Culture Detection Guide(Post)As a PhD student delving deep into the realm of cellular biology, there is one antagonist that consistently challenges my research: mycoplasma. This microscopic bacterium, with its a
Erenumab: Transforming Migraine Prevention Through CGRP Receptor Inhibition(Post)Quick Facts About ErenumabWhat is Erenumab?Erenumab is a fully human monoclonal antibody designed to prevent migraines by targeting the calcitonin gene-related peptide (CGRP) receptor.
ICOS: Stimulating the Immune System for Superior Cancer Therapy(Post)Immunotherapy has transformed the landscape of cancer treatment by leveraging the body’s immune system to target and destroy cancer cells. A key player in this process is Inducible T-cell
Do Not Eat Me Is Not a Switch(Post)Phagocytosis is a subtraction, not a switch. A macrophage engulfs when its activating signals exceed its inhibitory ones, and every awkward result in the myeloid checkpoint field falls out of that on
PI3K/AKT/mTOR Signalling in T Cells: Pathway, Function and Assays(Post)PI3K does not switch on a protein — it rewrites a membrane. Everything downstream follows from one chemical event: the 3-hydroxyl of a phosphoinositide is phosphorylated, PIP₂ becomes PIP₃, and every
Adipokines and Insulin Signaling Pathways: An In-Depth Exploration(Post)The prevalence of obesity and its associated metabolic disorders has risen dramatically in recent decades, presenting a significant global health challenge. Adipose tissue, once considered mere
CXC Chemokine Family(Post)In the realm of immunology, CXCL chemokines emerge as fascinating conductors. These small proteins, marked by their CXC motif, wield considerable influence over our immune responses and a ra
AKT Signalling – Mini Review(Post)Protein kinase B or AKT (PKB) is a serine/threonine kinase. In mammals it is comprised of 3 highly homologous isoforms PKBα (Akt1), PKBβ (Akt2), and PKBγ (Akt3) (Manning and Cantley 2007). AKT
Autophagy alterations in Alzheimer’s disease(Post)By Diana-Madalina Stan, PhD student, University of Salford Disease Description Alzheimer’s disease (AD), the most common cause of dementia, is a neu
p38 MAPK Signaling Review(Post)The p38 MAPK signaling pathway is an intracellular signaling pathway that plays a crucial role in cellular responses to various stressors and inflammatory stimuli. It is a part of the larger MAPK
Microglial Functions: Immune Response + Neuroinflammation(Post)Key Takeaways: Microglia are immune cells in the CNS, originating from myeloid precursor cells. They surveil the CNS, respond to changes, and maintain neural health. Microglia exist in diff
Adaptive immune system molecules(Page) Novel Gene Therapy for Cystic Fibrosis (Post)Novel Gene Therapies for Cystic Fibrosis Cystic Fibrosis Cystic fibrosis (CF) is an autosomal recessive, life-limiting disease resulting from gene mutations that encode the cystic fibr
Comprehensive Analysis of Antibody Structure and Function(Post)Antibodies, or immunoglobulins, stand as critical components of the immune system, orchestrating the identification and neutralization of pathogens like viruses and bacteria. This extensive artic
Citrullination, NETs and Rheumatoid Arthritis(Page) Bermekimab: Unveiling the Role of Anti-CD47 in Hidradenitis Suppurativa and Atopic Dermatitis(Post)What You Need to Know About BermekimabWhat is Bermekimab?Bermekimab is a monoclonal antibody targeting the CD47 receptor, developed to modulate the immune system and improve conditions l
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Icrucumab: Exploring the Role of Anti-Angiogenic Therapy in Cancer Research(Post)Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe